Cargando…
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is esse...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598436/ https://www.ncbi.nlm.nih.gov/pubmed/33145460 http://dx.doi.org/10.1016/j.adro.2020.10.003 |
_version_ | 1783602608819142656 |
---|---|
author | Zaorsky, Nicholas G. Yu, James B. McBride, Sean M. Dess, Robert T. Jackson, William C. Mahal, Brandon A. Chen, Ronald Choudhury, Ananya Henry, Ann Syndikus, Isabel Mitin, Timur Tree, Alison Kishan, Amar U. Spratt, Daniel E. |
author_facet | Zaorsky, Nicholas G. Yu, James B. McBride, Sean M. Dess, Robert T. Jackson, William C. Mahal, Brandon A. Chen, Ronald Choudhury, Ananya Henry, Ann Syndikus, Isabel Mitin, Timur Tree, Alison Kishan, Amar U. Spratt, Daniel E. |
author_sort | Zaorsky, Nicholas G. |
collection | PubMed |
description | PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic. |
format | Online Article Text |
id | pubmed-7598436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75984362020-11-02 Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 Zaorsky, Nicholas G. Yu, James B. McBride, Sean M. Dess, Robert T. Jackson, William C. Mahal, Brandon A. Chen, Ronald Choudhury, Ananya Henry, Ann Syndikus, Isabel Mitin, Timur Tree, Alison Kishan, Amar U. Spratt, Daniel E. Adv Radiat Oncol Scientific Article PURPOSE: During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions. METHODS AND MATERIALS: Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches. RESULTS: Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation. CONCLUSIONS: Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. 2020-11 2020-10-29 /pmc/articles/PMC7598436/ /pubmed/33145460 http://dx.doi.org/10.1016/j.adro.2020.10.003 Text en © 2020 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Scientific Article Zaorsky, Nicholas G. Yu, James B. McBride, Sean M. Dess, Robert T. Jackson, William C. Mahal, Brandon A. Chen, Ronald Choudhury, Ananya Henry, Ann Syndikus, Isabel Mitin, Timur Tree, Alison Kishan, Amar U. Spratt, Daniel E. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title | Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_full | Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_fullStr | Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_full_unstemmed | Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_short | Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19 |
title_sort | prostate cancer radiation therapy recommendations in response to covid-19 |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598436/ https://www.ncbi.nlm.nih.gov/pubmed/33145460 http://dx.doi.org/10.1016/j.adro.2020.10.003 |
work_keys_str_mv | AT zaorskynicholasg prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT yujamesb prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT mcbrideseanm prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT dessrobertt prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT jacksonwilliamc prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT mahalbrandona prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT chenronald prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT choudhuryananya prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT henryann prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT syndikusisabel prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT mitintimur prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT treealison prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT kishanamaru prostatecancerradiationtherapyrecommendationsinresponsetocovid19 AT sprattdaniele prostatecancerradiationtherapyrecommendationsinresponsetocovid19 |